S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Bank Accounts: Frozen! (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Bank Accounts: Frozen! (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Bank Accounts: Frozen! (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
The gold catalyst we’ve waited for (Ad)
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Bank Accounts: Frozen! (Ad)
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:AVTX

Avalo Therapeutics - AVTX Stock Forecast, Price & News

$1.85
-0.16 (-7.96%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.81
$2.08
50-Day Range
$1.85
$5.00
52-Week Range
$1.81
$11.28
Volume
48,985 shs
Average Volume
18,114 shs
Market Capitalization
$17.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Avalo Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.00 Rating Score
Upside/​Downside
737.8% Upside
$15.50 Price Target
Short Interest
Healthy
0.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.75mentions of Avalo Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.04) to ($2.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

766th out of 989 stocks

Pharmaceutical Preparations Industry

368th out of 480 stocks


AVTX stock logo

About Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. is a biopharmaceutical company. engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
AVTX Avalo Therapeutics, Inc.
Recap: Avalo Therapeutics Q3 Earnings
Avalo Therapeutics Announces Board Changes
See More Headlines
Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Company Calendar

Last Earnings
3/02/2022
Today
3/23/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTX
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+737.8%
Consensus Rating
Reduce
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-84,380,000.00
Net Margins
-293.77%
Pretax Margin
-293.37%

Debt

Sales & Book Value

Annual Sales
$5.40 million
Book Value
$2.47 per share

Miscellaneous

Free Float
5,140,000
Market Cap
$17.41 million
Optionable
Optionable
Beta
1.66

Key Executives

  • Garry Arthur Neil
    Chairman, President & Chief Executive Officer
  • Christopher SullivanChristopher Sullivan
    Chief Financial Officer
  • Lisa Hegg
    Vice President-Research & Development Programs
  • Colleen Matkowski
    Vice President-Global Regulatory Affairs













AVTX Stock - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AVTX shares.
View AVTX analyst ratings
or view top-rated stocks.

What is Avalo Therapeutics' stock price forecast for 2023?

1 brokers have issued 1 year target prices for Avalo Therapeutics' shares. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 737.8% from the stock's current price.
View analysts price targets for AVTX
or view top-rated stocks among Wall Street analysts.

How have AVTX shares performed in 2023?

Avalo Therapeutics' stock was trading at $5.0401 on January 1st, 2023. Since then, AVTX stock has decreased by 63.3% and is now trading at $1.85.
View the best growth stocks for 2023 here
.

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 24,800 shares, an increase of 30.5% from the February 13th total of 19,000 shares. Based on an average daily volume of 15,400 shares, the short-interest ratio is currently 1.6 days. Currently, 0.4% of the shares of the company are sold short.
View Avalo Therapeutics' Short Interest
.

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AVTX earnings forecast
.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its earnings results on Wednesday, March, 2nd. The company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.80) by $0.12. Avalo Therapeutics had a negative net margin of 293.77% and a negative trailing twelve-month return on equity of 950.78%.

When did Avalo Therapeutics' stock split?

Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Avalo Therapeutics' stock symbol?

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (5.75%), Millennium Management LLC (0.46%), Susquehanna International Group LLP (0.20%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avalo Therapeutics' stock price today?

One share of AVTX stock can currently be purchased for approximately $1.85.

How much money does Avalo Therapeutics make?

Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $17.41 million and generates $5.40 million in revenue each year.

How can I contact Avalo Therapeutics?

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com.

This page (NASDAQ:AVTX) was last updated on 3/24/2023 by MarketBeat.com Staff